Ibrutinib and rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisone in patients with previously untreated non‐germinal centre B‐cell‐like diffuse large B‐cell lymphoma: A Chinese subgroup analysis of the phase III PHOENIX trial

• Published in: EJHaem 2022-11, Vol.3 (4), p.1154-1164
• Main Authors: Zhu, Jun, Hong, Xiaonan, Song, Yu Qin, Hodkinson, Brendan, Balasubramanian, Sriram, Wang, Songbai, Zhang, Qingyuan, Shi, Yuankai, Huang, Huiqiang, Zhang, Huilai, Zhu, Yan, Shreeve, Stephen Martin, Sun, Steven, Wang, Ze, Wang, Xiaocan, Fan, Yue, Wilson, Wyndham, Vermeulen, Jessica
• Format: Article
• Language: English
• Subjects: Age; B-cell lymphoma; Biomarkers; Biopsy; China; Cyclophosphamide; DLBCL; Doxorubicin; Gene expression; Germinal centers; Histology; ibrutinib; Kinases; Lymphoma; Myc protein; Patients; Placebos; Prednisone; previously untreated; Rituximab; Vincristine
• ISSN: 2688-6146; 2688-6146
• DOI: 10.1002/jha2.517

In this post hoc subgroup analysis of 200 patients enrolled in China from the phase III PHOENIX trial (N = 838, NCT01855750), addition of ibrutinib to rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisone (R‐CHOP) did not improve event‐free survival (EFS) versus placebo+R‐CHOP in the intent‐to‐treat (ITT; n = 200, hazard ratio [HR] = 0.83, 95% confidence interval [CI]: 0·509–1.349; p = 0.4495) or activated B‐cell‐like (ABC; n = 141 [based on available gene‐expression profiling data], HR = 0.86, 95% CI: 0.467–1.570; p = 0.6160) subpopulations. However, ibrutinib+R‐CHOP improved EFS (HR = 0·50, 95% CI: 0.251–1.003) and progression‐free survival (PFS; HR = 0.48, 95% CI: 0.228–1.009) versus placebo+R‐CHOP in patients aged